New radioactive therapy targets hard-to-treat thyroid cancer
NCT ID NCT02088645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiation therapy. About 24 adults with progressive disease will take part to find the safest dose and measure how well the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Basel, Clinic for radiology and nuclear medicine
Basel, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive database study probes link between popular diabetes drugs and rare thyroid cancer
- New imaging agent could improve detection of rare cancers
- New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
- New hope for rare cancers? drug combo shows promise in early trial
- Thyroid cancer patients may spend less time in discomfort with simple phone calls
- Custom mRNA vaccine takes on rare endocrine cancers